Overview

This trial is active, not recruiting.

Conditions intra-abdominal infections, skin disease, infectious
Treatment tigecycline (tygacil)
Sponsor Pfizer
Start date April 2013
End date January 2017
Trial size 100 participants
Trial identifier NCT01789905, B1811187

Summary

To retrospectively collect the effectiveness and safety information of tigecycline related to their appropriate use in daily practice.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective
Arm
Subjects who are treated with tigecycline
tigecycline (tygacil) Tygacil, Tigecycline
Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.

Primary Outcomes

Measure
Number of Participants with Clinical Response of Cure at the Test-of-Cure (TOC) Visit
time frame: 14 days

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - All patients who are prescribed tigecycline (Tygacil). Exclusion Criteria: - Subject who have been prescribed tigecycline (Tygacil).

Additional Information

Official title Tygacil Drug Use Investigation (Tigecycline Evaluation Study For Safety And Effectiveness In Patient Infected With Multi-drug Resistance.)
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Pfizer.